Insights on Life Sciences


The Next Normal – The future of biotech: AI-driven drug discovery

– Many diseases today don’t have a cure. One reason is that drug discovery is difficult: finding and developing an effective medicine is a yearslong and very expensive process. But maybe it doesn’t have to be. Experts say AI—if properly integrated into scientists’ research—could revolutionize drug discovery, making it possible for more patients to get the treatments they need.

The Helix report: Is biopharma wired for future success?

– The biopharmaceutical industry has made remarkable achievements in the past decade, but is it equipped to leap still further ahead... in the coming one? Company leaders’ answers to nine questions could prove decisive.

How AI can accelerate R&D for cell and gene therapies

– Cell and gene therapies show significant promise but need substantial innovation to unlock full potential for patients. Scaling... digital and analytics in discovery and R&D is part of the solution.

Putting the patient first: A conversation with Roche’s Moritz Hartmann

– The global head of information solutions for a leading healthcare provider explains the importance of technological and management... innovation in helping to serve patients in new ways.

Building greater resilience in vaccine manufacturing

– The COVID-19 pandemic has highlighted the need for resilience in vaccine manufacturing. Five considerations can help national public-health... leaders plan.

Innovation sourcing in biopharma: Four practices to maximize success

– Biopharma companies’ pipelines are full of assets they source externally to access innovation. Four practices will help... ensure their investments flourish at a time of fierce competition.

Reimagining the future of biopharma manufacturing

– Leveraging digital and analytics advances can unlock significant value for biopharma companies through gains in quality, speed,... agility, and resilience.

AI in biopharma research: A time to focus and scale

– By focusing on specific scientific and operational pain points and fully integrating AI into research workflows, biopharma companies... can deliver greater patient impact and significant value.

Emerging from disruption: The future of pharma operations strategy

– To maintain profitable and resilient operations, CEOs and COOs of pharma companies may need to make bold changes to their operations... strategy as the industry navigates new challenges.

Special collection

Future of pharma operations

Pharma companies are experiencing a wave of innovations – from new treatment modalities, to smart machines, advanced analytics, and digital connectivity. This selection of articles presents strategies and insights to capitalize on these innovations and advance quality, efficiency, resilience, and workforce agility in pharma operations. Contact us to learn more.

Coronavirus vaccines progress: What’s next?

The rapid development of the COVID-19 vaccines is having a profound effect on the world. This collection takes a closer look at the development, rollout and future of vaccines.

McKinsey insights on cell and gene therapy

Continuing advances in cell and gene therapy (CGT) are transforming how biopharma companies treat and potentially cure certain diseases. Browse our collection of articles for an in-depth look at the opportunities, challenges, and implications for stakeholders in this fast-evolving field, and explore how McKinsey’s new Digital Capability Center for Cell and Gene Therapy will help biopharma companies accelerate digital transformations in manufacturing and the journey to operational excellence. Contact us to learn more.

The rise of health technology

Health technology continues to push the boundaries of how healthcare is delivered and has the power to create breakthroughs in our understanding of disease. This collection of articles and interviews explores the evolving role of health technology in the life-sciences sector and implications for key stakeholders. Contact us to learn more about our work in this field.

Want to learn more about how we help clients in Life Sciences?

More insights


How AI could revolutionize drug discovery

– Artificial intelligence could help scientists develop better medicines faster—and thus improve millions of people’s... lives. But for that to happen, companies will need to change the way they work.

Vineeta Agarwala on the promise—and limits—of AI in drug discovery

– By helping us learn from every single patient and every piece of data, AI could enable medical breakthroughs, says Andreessen... Horowitz general partner Vineeta Agarwala.

‘It will be a paradigm shift’: Daphne Koller on machine learning in drug discovery

– We’re entering a “new era of science”—we finally have enough data and technology to truly enable better... drugs for patients, says insitro CEO Daphne Koller.

‘We can invent new biology’: Molly Gibson on the power of AI

– The cofounder of Generate Biomedicines, a pioneering new drug development platform, describes how AI and machine learning are... transforming the way we discover new medicines.

How the European biotech sector can navigate turbulent times

– The recent market downturn has affected biotechs worldwide. But the fundamentals are still strong in Europe, where companies have... an opportunity to lead the next phase of bioscience innovation.

Emerging from disruption: The future of pharma operations strategy

– To maintain profitable and resilient operations, CEOs and COOs of pharma companies may need to make bold changes to their operations... strategy as the industry navigates new challenges.

Developing a customer-centric approach to rare conditions

– In this interview, Roche Pharmaceuticals’ rare-conditions leaders discuss their organization’s approach to rare diseases... and their industry’s efforts to make a difference.

Eight imperatives for launching cell and gene therapies

– Companies launching new cell and gene therapies can live up to their promise of transforming patient lives through proper preparation... of the market, their products, and internal go-to-market models.

A biotech survival kit for a challenging public-market environment

– After a decade of plenty, biotechs are grappling with a challenging market. To emerge strongly, they can streamline R&D and... G&A expenses, evaluate new financing options, and consider mergers with other biotechs.

Out of the shadows: A brighter future for pharma technical development

– The sometimes-overlooked function of chemistry, manufacturing, and controls (CMC) has a rare opportunity to reimagine its role... and find innovative ways to improve and accelerate drug development.

Against the odds: How life sciences companies excel in large transformations

– Life sciences companies pursuing a step change in performance have obtained mixed results. Adhering to five principles can greatly... improve the odds of a large transformation program succeeding.
Sorry, we couldn't find any results. Try removing some filters.

Connect with our Life Sciences Practice